$132.73−5.20 (−3.77%)
At close: Oct 1, 2026, 4:00 PM ET
Palvella Therapeutics, Inc. · Statistics
Cheap or expensive, strong or fragile. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.
VALUE
Rich vs sector
premium price vs peers
QUALITY
Weak
below-peer returns
HEALTH
Sturdy
conservative balance sheet
GROWTH
No data
insufficient peers
In one line
A weak business at a rich price for its sector: value 5, quality 29, health 73, each a percentile within Healthcare.
On October 2, 2026 the Tenet Score and these statistics moved from the latest fiscal year to the trailing twelve months, for companies that file quarterly statements. Scores before October 2, 2026 were computed on fiscal-year figures.
Every figure here is from the latest fiscal year. The note under each row says why.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own 10-year record (context, not scored)hover any metric for its formula
Valuation
5th pctilepremium price vs peersEBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.—excluded: no value on file for this company
Financial health
73rd pctileconservative balance sheet(Cash, short-term investments and receivables) ÷ current liabilities, as the data vendor builds it. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.5.2067th pctileFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
(Total debt − cash) ÷ EBITDA—excluded: negative EBITDA denominator
Profitability & returns
29th pctilebelow-peer returns−149%7th pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
Altman's bankruptcy-distance score for the latest fiscal year, with its market-value term at the fiscal year end; higher is safer, as the data vendor publishes it (vendor definition, not reproduced).32.994th pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
Growth
insufficient peers★ Corrected metrics: why we compute these ourselves
the receipts behind the numbers aboveGreenblatt earnings yield—EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC−80%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage— Guarded, not faked: we have no interest-expense figure on file for this company, so it's excluded from the ranking instead of rendered as garbage.
Every raw line behind these ratios→
All three statements: 5 years free, 10 on Premium, 20 on Ultimate
Quarterly, in fiscal years: 1 free, 5 on Premium, Unlimited on Ultimate
These percentiles feed the value, income, timing and long-hold tenets→
See which criteria pass, with the live number and the rule behind each
Percentiles computed nightly against 400 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value sits in the company's own ten-year annual record, shown for context and never blended into the score. Computed 2026-10-02 · Not investment advice.